ClinicalTrials.Veeva

Menu

To Study Different Levels of MK0493 for Safety, Efficacy, and Tolerability in Obese Patients (0493-017)(COMPLETED)

Merck Sharp & Dohme (MSD) logo

Merck Sharp & Dohme (MSD)

Status and phase

Completed
Phase 2

Conditions

Obesity

Treatments

Drug: MK0493

Study type

Interventional

Funder types

Industry

Identifiers

NCT00482196
2007_577
0493-017

Details and patient eligibility

About

To study different doses of MK0493 for safety, efficacy and tolerability in obese patients.

Enrollment

173 patients

Sex

All

Ages

21 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient is between 21 and 65 years of age

Exclusion criteria

  • HIV positive as determined by medical history
  • Patient is pregnant, lactating or plans to become pregnant
  • Patient has undergone surgical treatment for obesity
  • Patient has undergone a surgical procedure within 4 weeks prior to Visit 1 or plans to undergo a surgical procedure during the study
  • Patient plans to consume more than 2 glasses of grapefruit juice per day during the study
  • Patient has participated in another clinical study (involving an investigational drug) within 3 months prior to restudy screening

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems